Clinical Trial Update: Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating CHF1535 delivered via NEXT DPI compared with a pMDI and BDP DPI in asthma patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CHF1535

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 3 | Status: COMPLETED